Cenicriviroc

Generic Name: Cenicriviroc

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₄₁H_₅₂N_₄O_₄S

CAS Number: 497223-25-3

Unique Ingredient Identifier: 15C116UA4Y

Background: Cenicriviroc has been used in trials studying the treatment of HIV-infection/AIDS, AIDS Dementia Complex, Nonalcoholic Steatohepatitis, Human Immunodeficiency Virus, and HIV-1-Associated Cognitive Motor Complex.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Phase 2

Recruiting

Conditions: COVID-19

Interventions: Drug: Remdesivir
Drug: Imatinib Mesylate
Drug: Dexamethasone
Biological: dornase alfa
Drug: Celecoxib
Biological: IC14
Biological: narsoplimab
Drug: Cenicriviroc
Drug: Apremilast
Drug: Icatibant
Drug: Aviptadil
Drug: Cyproheptadine
Drug: Cyclosporine
Drug: Famotidine

First Posted Date: 2020-07-27

Last Posted Date: 2024-03-19

Lead Sponsor: QuantumLeap Healthcare Collaborative

Target Recruit Count: 1500

Registration Number: NCT04488081

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Sanford Health, Sioux Falls, South Dakota, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

and more 33 locations

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Cenicriviroc

First Posted Date: 2017-12-19

Last Posted Date: 2018-01-11

Lead Sponsor: Allergan

Target Recruit Count: 16

Registration Number: NCT03376841

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Phase 2

Terminated

Conditions: Nonalcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
Liver Cirrhosis

Interventions: Drug: Cenicriviroc

First Posted Date: 2017-02-23

Last Posted Date: 2022-02-02

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 167

Registration Number: NCT03059446

Locations: 🇩🇪
Universitaetsklinikum Heidelberg - Innere Medizin IV, Heidelberg, Germany
🇩🇪
Uniklinik Koeln, Poliklinik fuer Endokrinologie, Diabetologie und Praeventivmedizin (ZEDP), Koeln, Germany
🇬🇧
Queen Alexandra Hospital, Portsmouth, United Kingdom

and more 68 locations

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

Phase 3

Terminated

Conditions: Nonalcoholic Steatohepatitis

Interventions: Drug: Placebo
Drug: Cenicriviroc

First Posted Date: 2017-01-23

Last Posted Date: 2022-03-10

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 1778

Registration Number: NCT03028740

Locations: 🇺🇸
Gastroenterology Associates of Fairfield County, Bridgeport, Connecticut, United States
🇺🇸
Qway Research, LLC, Hialeah, Florida, United States
🇺🇸
Options Health Research, Tulsa, Oklahoma, United States

and more 336 locations

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cenicriviroc
Drug: Famotidine
Drug: Omeprazole

First Posted Date: 2016-02-18

Last Posted Date: 2017-11-24

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 48

Registration Number: NCT02684799

Locations: 🇺🇸
SeaView Research, Inc., Miami, Florida, United States

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cenicriviroc
Drug: Pioglitazone

First Posted Date: 2015-01-19

Last Posted Date: 2015-05-12

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 20

Registration Number: NCT02342067

Locations: 🇺🇸
DaVita Clinical Research, Lakewood, Colorado, United States

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis

Interventions: Drug: Cenicriviroc
Drug: Placebo

First Posted Date: 2014-08-15

Last Posted Date: 2019-05-10

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 289

Registration Number: NCT02217475

Effect of Cenicriviroc on HIV Neurocognitive Impairment

Phase 2

Completed

Conditions: AIDS Dementia Complex
HIV-1-Associated Cognitive Motor Complex
Human Immunodeficiency Virus

Interventions: Drug: cenicriviroc

First Posted Date: 2014-05-01

Last Posted Date: 2020-08-20

Lead Sponsor: University of Hawaii

Target Recruit Count: 20

Registration Number: NCT02128828

Locations: 🇺🇸
Clint Spencer Clinic, Honolulu, Hawaii, United States

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

Phase 1

Completed

Conditions: HIV-infection/AIDS

Interventions: Drug: Cenicriviroc
Drug: Dolutegravir
Drug: Midazolam

First Posted Date: 2013-04-09

Last Posted Date: 2014-04-09

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 20

Registration Number: NCT01827540

Locations: 🇺🇸
SeaView Research, Inc., Miami, Florida, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy